Raquel Puerta MSc,Itziar de Rojas PhD,Pablo Garcia-Gonzalez MSc,Claudia Olive MSc,Oscar Sotolongo-Grau PhD,Ainhoa Garcia-Sanchez MSc,Fernando Garcia-Gutierrez MSc,Laura Montrreal,Juan Pablo Tartari,Angela Sanabria PhD,Vanesa Pytel PhD,Carmen Lage MD,Ines Quintela PhD.,Nuria Aguilera,Eloy Rodriguez-Rodriguez MD, PhD,Emilio Alarcon-Martin MSc,Adelina Orellana PhD,Pau Pastor MD, PhD,Jordi Perez-Tur PhD,Gerard Pinol-Ripoll PhD,Adolfo Lopez de Munian MD PhD,Jose Maria Garcia-Alberca MD, PhD,Jose Luis Royo PhD,Maria Bullido PhD,Victoria Alvarez PhD,Luis Miguel Real PhD,Arturo Corbaton Anchuelo MD, PhD,Dulcenombre Gomez-Garre PhD,Maria Teresa Martinez Larrad MD, PhD,Emilio Franco-Macias,Pablo Mir MD, PhD,Miguel Medina PhD.,Raquel Sanchez-Valle MD, PhD,Oriol Dols-Icardo PhD,Maria Eugenia Saez PhD,Angel Carracedo PhD,Lluis Tarraga MSc,Montse Alegret PhD,Sergi Valero PhD,Marta Marquie MD, PhD,Merce Boada MD, PhD,Pascual Sanchez Juan MD, PhD,Jose Enrique Cavazos PhD,Alfredo Cabrera PhD,Amanda Cano PhD,Agustin Ruiz MD, PhD

Abstract:Background: Alzheimer's disease (AD) has a high heritable component characteristic of complex diseases, yet many of the genetic risk factors remain unknown. We combined genome-wide association studies (GWAS) on amyloid endophenotypes measured in cerebrospinal fluid (CSF) and positron emission tomography (PET) as surrogates of amyloid pathology, which may be helpful to understand the underlying biology of the disease. Methods: We performed a meta-analysis of GWAS of CSF Aβ42 and PET measures combining six independent cohorts (n=2,076). Due to the opposite effect direction of Aβ, phenotypes in CSF and PET measures, only genetic signals in the opposite direction were considered for analysis (n=376,599). Polygenic risk scores (PRS) were calculated and evaluated for AD status and amyloid endophenotypes. We then searched the CSF proteome signature of brain amyloidosis using SOMAscan proteomic data (Ace cohort, n=1,008) and connected it with GWAS results of loci modulating amyloidosis. Finally, we compared our results with a large meta-analysis using publicly available datasets in CSF (n=13,409) and PET (n=13,116). This combined approach enabled the identification of overlapping genes and proteins associated with amyloid burden and the assessment of their biological significance using enrichment analyses. Results: After filtering the meta-GWAS, we observed genome-wide significance in the rs429358-APOE locus and nine suggestive hits were annotated. We replicated the APOE loci using the large CSF-PET meta-GWAS and identified multiple AD-associated genes as well as the novel GADL1 locus. Additionally, we found a significant association between the AD PRS and amyloid levels, whereas no significant association was found between any Aβ, PRS with AD risk. CSF SOMAscan analysis identified 1,387 FDR-significant proteins associated with CSF Aβ42 levels. The overlap among GWAS loci and proteins associated with amyloid burden was very poor (n=35). The enrichment analysis of overlapping hits strongly suggested several signalling pathways connecting amyloidosis with the anchored component of the plasma membrane, synapse physiology and mental disorders that were replicated in the large CSF-PET meta-analysis. Conclusions: The strategy of combining CSF and PET amyloid endophenotypes GWAS with CSF proteome analyses might be effective for identifying signals associated with the AD pathological process and elucidate causative molecular mechanisms behind the amyloid mobilization in AD.

Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer's disease

Identification of Candidate Biomarkers of Alzheimer's Disease Via Multiplex Cerebrospinal Fluid and Serum Proteomics.

Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.

Characterization of proteome of human cerebrospinal fluid.

Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer’s disease pathogenesis

Genetic architecture of cerebrospinal fluid and brain metabolite levels and the genetic colocalization of metabolites with human traits

Connecting dementia risk loci to the CSF proteome identifies pathophysiological leads for dementia

Identification of novel drug targets for Alzheimer’s disease by integrating genetics and proteomes from brain and blood

Identification of Novel Drug Targets for Alzheimer's Disease by Integrating Genetics and Proteomes from Brain and Blood.

Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers

A genetic and proteomic comparison of key AD biomarkers across tissues

Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease

Proteome-wide association studies using summary pQTL data of three tissues identified 30 risk genes of Alzheimer's disease dementia

Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer’s disease

Multivariate GWAS of Alzheimer's disease CSF biomarker profiles implies GRIN2D in synaptic functioning

Connecting genomic and proteomic signatures of amyloid burden in the brain

Proteogenomics in cerebrospinal fluid and plasma reveals new biological fingerprint of cerebral small vessel disease

CSF proteomics identifies early changes in autosomal dominant Alzheimer's disease

Multiplex Cerebrospinal Fluid Proteomics Identifies Biomarkers for Diagnosis and Prediction of Alzheimer’s Disease

The genetic landscape of neuro-related proteins in human plasma

Targeted proteomic profiling in cerebrospinal fluid and plasma identifies biomarkers for Alzheimer’s disease